A daily pill just doubled survival time for advanced pancreatic cancer

BY THE OPTIMIST DAILY EDITORIAL TEAM In a 500-patient trial at American Society of Clinical Oncology’s (ASCO) annual meeting in Chicago, a daily pill called daraxonrasib doubled average survival time in patients with advanced pancreatic cancer. Those on the drug lived for an average of 13.2 months. Those on standard chemotherapy lived for 6.6 to […] The post A daily pill just doubled survival time for advanced pancreatic cancer first appeared on The Optimist Daily: Making Solutions the News.